Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | 62.72% | 0.00% | 5.11% | 0.00% |
| Total Depreciation and Amortization | 0.00% | 17.22% | 0.00% | 8.88% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -151.07% | 0.00% | 141.01% | 0.00% |
| Change in Net Operating Assets | 0.00% | 313.14% | 0.00% | -193.45% | 0.00% |
| Cash from Operations | 0.00% | 52.43% | 0.00% | 9.18% | 0.00% |
| Capital Expenditure | -- | -- | 0.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -100.00% | 0.00% |
| Other Investing Activities | 0.00% | 96.88% | 0.00% | -2,233.33% | 0.00% |
| Cash from Investing | 0.00% | 99.66% | 0.00% | -19,433.33% | 0.00% |
| Total Debt Issued | 0.00% | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 2.47% | 0.00% | 11.23% | 0.00% |
| Issuance of Common Stock | -- | -- | 0.00% | 78.83% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 98.90% | 0.00% | -1,093.26% | 0.00% |
| Cash from Financing | 0.00% | -90.78% | 0.00% | 58.68% | 0.00% |
| Foreign Exchange rate Adjustments | 0.00% | 122.78% | 0.00% | -256.44% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | -208.17% | 0.00% | 239.66% | 0.00% |